Simon Read

Scientific Advisor at Q32 Bio

Simon is an Entrepreneur-in-Residence at Atlas. Prior to joining Atlas, Simon was CSO at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma. Simon brings to Atlas more than 25 years of R&D experience including leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech. Simon has worked on the clinical development of some of the most well-known drugs in the immunology area, including Rituxan® and Actemra®. Simon is a Fellow of the Royal Society of Medicine (UK) and a board member of Oxstem Therapeutics. He obtained his Ph.D. from University of Hertfordshire and studied Physiology at the University of Manchester in the UK. Simon is well published, having authored over 50 articles in peer reviewed journals.

Links

Timeline

  • Scientific Advisor

    Current role